Originally published by our sister publication Gastroenterology & Endoscopy News
Patients taking the glucagon/glucagon-like peptide-1 receptor dual agonist survodutide saw an 83% improvement in their metabolic dysfunction–associated steatohepatitis symptoms, as well as significant improvement in liver fibrosis stages F1, F2 and F3, according new research presented at DDW 2024 and EASL Congress 2024.
This improvement in MASH symptoms translates to a 64.8% (95% CI, 51.1%-78.6%) difference